Recent Grants 

The Office of Grants and Sponsored Programs would like to convey our pride and appreciation for the awards received with a project start date of October 1, 2013 to March 31, 2014.

Primary
Investigator

Title of Award

Awarding Agency

Andrea Benin, MD

Using the Adverse Event Reporting System: Can Analysis be Streamlined by Text Processing?

American Society for Healthcare Risk Management (ASHRM)

Craig Lapin, MD

Therepeutic Development Center 2014

Cystic Fibrosis Therapeutic Foundation

Donna Boruchov, MD

ATHN - My Life, Our Future

American Thrombosis Hemostasis Network

Donna Boruchov, MD

Cancer Funds 2

University of Connecticut Health Center

Francisco Sylvester, MD

Intestinal Gamma Delta T Cell Responses in Newly Diagnosed Inflammatory Bowel Disease

Oregon Health & Science University / University of Connecticut Health Center

Juan Salazar, MD

Ryan White A 2014-2015

U.S. Department of Health Resources Service Administration (HRSA)

Kerry Moss, MD

Hyundai Hope Scholar Grant

Hyundai Hope

Marilyn Sanders, MD

Decreasing Non-Medically Indicated Deliveries at <39 Weeks' Gestation: A Hartford Regional Demonstration Project Final Meeting

March of Dimes

Michelle Cloutier, MD

Easy Breathing Training 2013-14

Community Health Network

Michelle Cloutier, MD

Building Bridges 2013-14

Glaxo Smith / National Jewish Health

Nehal Parikh, MD

Advanced Therapeutics Development

St. Baldrick's Foundation

Paul Dworkin, MD

Innovations in Care Coordination: A Community Systems Approach

Connecticut Health Foundation

Paul Dworkin, MD

Hartford Blueprint Project - Matching Funds 13-14

Hartford Foundation for Public Giving

William Zempsky, MD

SEED (Strategies for Education in Emergency Department) Greater Understanding of Sickle Cell Disease

The Donaghue Foundation

Garry Lapidus, PA-C

Address Lift Assist Calls

Connecticut's Department of Social Services

Kevin Borrup, JD, MBA

Road Mentor: New Driver 13-14

Connecticut Health and Educational Facilities

Kevin Borrup, JD, MBA

DOT Child Passenger Safety 2014-2015

Connecticut Department of Transportation

New Clinical Trials

Congratulations to the PIs whose studies have recently opened: 

Study Name

Sponsor

PI

Division

A three-armed, randomized, double blind, placebo controlled study of the efficacy and safety of two trough ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex who have refractory partial onset seizures.

Novartis Pharmaceutical Corporation

Francis DiMario, MD

Neurology

A phase 1b open label study to assess the safety and pharmacokinetics of subcutaneously administered golimumab, a human anti-TNF antibody, in pediatric subjects with moderately to severely active ulcerative colitis.

Janssen Research & Development LLC

Jeffrey Hyams, MD

Gastroenterology

Registrat MAPI: VTPP 510

Registrat-MAPI

Craig Lapin, MD

Pulmonary Medicine

A phase 1b, open label, multicenter study to investigate the pharmacokinetics, pharmacodynamics and safety of Tocilizumab following subcutaneous administration to patients with polyarticular-course juvenile idiopathic arthritis.

Hoffman-La Roche Limited

Lawrence Zemel, MD

Rheumatology

A phase 1b, open label, multicenter study to investigate the pharmacokinetics, pharmacodynamics and safety of Tocilizumab following subcutaneous administration to patients with systemic juvenile idiopathic arthritis.

Hoffman-La Roche Limited

Lawrence Zemel, MD

Rheumatology

Single-dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in pediatric subjects at risk for a venous or arterial thrombotic disorder.

Bristol Myers Squibb Oncology

Donna Boruchov, MD

Hematology/Oncology

A phase 3, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 12 years or older with cystic fibrosis, homozygous for the F508-del-CFTR mutation.

Vertex Pharmaceuticals, Inc.

Craig Lapin, MD

Pulmonary Medicine

Pediatric patients with acute hematogenous osteomyelitis.

Cubist Pharmaceuticals, Inc.

Nicholas Bennett, MD

Infectious Disease

Pediatric intravenous versus oral antibiotic therapy.

Children's Hospital of Philadelphia

Ilana Waynik, MD

Inpatient Management Team

CCFA Partners-Pediatrics

Emory University

Jeffrey Hyams, MD

Gastroenterology

A prospective, randomized, double blind, sham controlled, multi center, phase 3 study of OTO-201 given as a single intratympanic injection for intra-operative treatment of middle ear effusion in pediatric subjects requiring tympanostomy tube placement.

Otonomy, Inc.

Scott Schoem, MD

Otolaryngology

Randomized, parallel dose, phase 1/2 safety and pharmacokinetics study of inhaled laninamivir octanoate twincaps dry powder inhaler in children with naturally acquired influenze A or B.

PPD Development, Inc.

Nicholas Bennett, MD

Infectious Disease

A phase 3, multicenter, open label study to evaluate pharmacokinetics, efficacy and safety of Abatacept administered subcutaneously in children and adolescents with active polyarticular juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease modifying anti-rheumic drugs.

Bristol Myers Squibb

Lawrence Zemel, MD

Rheumatology